Development and validation of an AI-enhanced prediction model for 3-year visual decline in patients with diabetes using ophthalmic imaging: protocol for a real-world longitudinal cohort study
9 affiliations
- 1School of Biomedical Engineering, Hainan University, Sanya, Hainan, China
- 2Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
- 3Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China
- 4Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration, Hainan Real-World Data Research Institute, Lecheng, Hainan, China
- 5Department of Ophthalmology, Peking University Third Hospital, Beijing, China
- 6Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Peking University Third Hospital, Beijing, China
- 7Ningbo Key Laboratory of Medical Research on Blinding Eye Diseases, Ningbo Eye Institute, Wenzhou Medical University, Ningbo Eye Hospital, Ningbo, Zhejiang, China
- 8Laboratory of Advanced Theranostic Materials and Technology, Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences, Ningbo, China
- 9Department of Epidemiology and Biostatistics, Peking University, Beijing, China
Abstract
Background: Diabetic retinopathy (DR) is one of the leading causes of visual impairment among working-age adults worldwide. Existing artificial intelligence (AI) studies have mainly focused on automated diagnosis and grading of DR or diabetic macular oedema while relatively few studies have investigated long-term prediction of visual outcomes. In clinical practice, patients and clinicians are more concerned about whether future visual decline will occur rather than merely identifying the current presence of DR. This study aims to develop and validate a real-world prognostic model integrating AI-derived imaging scores, ophthalmic examinations and systemic clinical variables to predict 3-year visual decline in patients with diabetes.
Methods and analysis: This retrospective longitudinal cohort study will use routinely collected ophthalmic imaging and clinical data from Peking University Third Hospital for model development and internal validation, with independent external validation planned using data from Ningbo Eye Hospital, Wenzhou Medical University. The development cohort will cover the period from 1 January 2018 to 1 May 2026. Eligible eyes will have baseline colour fundus photography (CFP) and/or optical coherence tomography (OCT), baseline best-corrected visual acuity and at least one follow-up visual acuity record within 3 years after the index date. CFP-enhanced analyses will include eyes with eligible CFP, OCT-enhanced analyses will include eyes with eligible OCT and multimodal analyses will require eligible paired CFP and OCT. The primary outcome will be time to first visual decline within 3 years, defined as an increase in logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity of ≥0.2 from baseline in the same eye. Sustained visual decline, requiring confirmation of a ≥0.2-logMAR deterioration at a subsequent eligible visit, will be evaluated as a key secondary outcome. AI-derived imaging scores will be generated using prespecified modality-specific and multimodal retinal image models. Separate CFP and OCT models will generate continuous CFP-derived and OCT-derived imaging scores, while a prespecified multimodal model jointly integrating paired CFP and OCT information will generate a single continuous multimodal imaging score. These imaging scores will be incorporated separately into prespecified AI-enhanced prognostic models together with demographic, systemic and ophthalmic predictors. Cox regression, penalised Cox regression and exploratory machine learning survival models will be developed and internally validated and the final prognostic model will be externally evaluated in an independent cohort from Ningbo Eye Hospital. Performance will be evaluated using discrimination, calibration, Brier score and decision curve analysis.
Ethics and dissemination: This study has received ethical approval from the Ethics Committee of Peking University Third Hospital (approval number: IRB00006761-M20260399). All data will be de-identified before analysis. The findings of this study will be disseminated through peer-reviewed publications and conferences.
Related
- Prediction of incident inflammatory bowel disease from routine electronic health records: development and external validation of a longitudinal machine learning model
- Mixed Reality-Based Slit Lamp for Ophthalmic Examination and Telemedicine: Technological Development and Validation Study.
- Risk factors for post-PCI restenosis in patients with coronary heart disease and the development and validation of a nomogram prediction model
- Development and internal validation of an exploratory clinical prediction model for MRI-defined white matter injury in moderate-to-late preterm infants: a single-center retrospective study
- Development and internal validation of a machine learning prediction model for postoperative hemorrhage following modified radical mastectomy for breast cancer
BibTeX
@article{yu2026development,
title = {{Development and validation of an AI-enhanced prediction model for 3-year visual decline in patients with diabetes using ophthalmic imaging: protocol for a real-world longitudinal cohort study}},
author = {Yexian Yu and Jiarui Yang and Yanyan Zhang and Shaodong Ma and Jing Hong and Shan Nan and Feng Sun},
journal = {BMJ Open},
year = {2026},
month = sep,
doi = {10.1136/bmjopen-2026-123521},
url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-123521},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Development and validation of an AI-enhanced prediction model for 3-year visual decline in patients with diabetes using ophthalmic imaging: protocol for a real-world longitudinal cohort study
AU - Yexian Yu
AU - Jiarui Yang
AU - Yanyan Zhang
AU - Shaodong Ma
AU - Jing Hong
AU - Shan Nan
AU - Feng Sun
PY - 2026
DA - 2026/09/30
JO - BMJ Open
DO - 10.1136/bmjopen-2026-123521
UR - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-123521
AB - Background: Diabetic retinopathy (DR) is one of the leading causes of visual impairment among working-age adults worldwide. Existing artificial intelligence (AI) studies have mainly focused on automated diagnosis and grading of DR or diabetic macular oedema while relatively few studies have investigated long-term prediction of visual outcomes. In clinical practice, patients and clinicians are more concerned about whether future visual decline will occur rather than merely identifying the current presence of DR. This study aims to develop and validate a real-world prognostic model integrating AI-derived imaging scores, ophthalmic examinations and systemic clinical variables to predict 3-year visual decline in patients with diabetes. Methods and analysis: This retrospective longitudinal cohort study will use routinely collected ophthalmic imaging and clinical data from Peking University Third Hospital for model development and internal validation, with independent external validation planned using data from Ningbo Eye Hospital, Wenzhou Medical University. The development cohort will cover the period from 1 January 2018 to 1 May 2026. Eligible eyes will have baseline colour fundus photography (CFP) and/or optical coherence tomography (OCT), baseline best-corrected visual acuity and at least one follow-up visual acuity record within 3 years after the index date. CFP-enhanced analyses will include eyes with eligible CFP, OCT-enhanced analyses will include eyes with eligible OCT and multimodal analyses will require eligible paired CFP and OCT. The primary outcome will be time to first visual decline within 3 years, defined as an increase in logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity of ≥0.2 from baseline in the same eye. Sustained visual decline, requiring confirmation of a ≥0.2-logMAR deterioration at a subsequent eligible visit, will be evaluated as a key secondary outcome. AI-derived imaging scores will be generated using prespecified modality-specific and multimodal retinal image models. Separate CFP and OCT models will generate continuous CFP-derived and OCT-derived imaging scores, while a prespecified multimodal model jointly integrating paired CFP and OCT information will generate a single continuous multimodal imaging score. These imaging scores will be incorporated separately into prespecified AI-enhanced prognostic models together with demographic, systemic and ophthalmic predictors. Cox regression, penalised Cox regression and exploratory machine learning survival models will be developed and internally validated and the final prognostic model will be externally evaluated in an independent cohort from Ningbo Eye Hospital. Performance will be evaluated using discrimination, calibration, Brier score and decision curve analysis. Ethics and dissemination: This study has received ethical approval from the Ethics Committee of Peking University Third Hospital (approval number: IRB00006761-M20260399). All data will be de-identified before analysis. The findings of this study will be disseminated through peer-reviewed publications and conferences.
SN - 2044-6055
SN - 2044-6055
ER -